Pharmaceutical News

RSS

Researchers transform yellow fever vaccine to fend off mosquito borne parasites that cause malaria

There is no vaccine for malaria, which sickens almost a quarter of a billion people each year and kills a child every 30 seconds. That could be changing: researchers at The Rockefeller University have genetically transformed the yellow fever vaccine to prime the immune system to fend off the mosquito borne parasites that cause the disease.

14 Jun 2010

ACIP's new immunization guidelines for upcoming year

Summer is all about barbeques and lazy days at the pool. It's also a good time to start thinking about preparing for flu season, and the vaccinations you or your child may need for the upcoming year, says Carrie Maffeo, a professor of pharmacy at Butler University, who specializes in immunizations.

14 Jun 2010

Customs Organization to sign declaration against counterfeit drugs

The World Customs Organization will sign a declaration to fight the $200-billion-a-year counterfeit drug industry, Reuters reports.

14 Jun 2010

BIOTECanada congratulates CPHA on 100 years of leadership in public health

As a community partner of the Canadian Public Health Association, BIOTECanada, on behalf of Canada's biotechnology industry, congratulates the CPHA on 100 years of leadership in public health.

11 Jun 2010

FDA grants orphan drug designation for ICT-107

ImmunoCellular Therapeutics announced today that the U.S. Food and Drug Administration has granted orphan drug designation for ICT-107, the company's dendritic cell-based cancer vaccine candidate which targets glioblastoma multiforme. As a result of the orphan drug status, ImmunoCellular will be eligible to receive a number of benefits, including access to grant funding for clinical trials, tax credits, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of up to seven years.

11 Jun 2010

PRA International to host interactive round-table sessions on drug development, lifecycle management

PRA International, a leading Clinical Research Organization, will host five interactive round-table sessions on drug development and lifecycle management at the Drug Information Association's annual meeting in Washington, D.C. 13-17 June 2010.

11 Jun 2010

Waismann Method survey: 88% of individuals taken prescription painkillers for chronic pain relief

According to a recent survey conducted by the Waismann Method of opiate detoxification, doctors prescribing medication for the treatment of chronic pain were found to be the leading source of prescription painkiller use. Approximately 88 percent of all respondents stated they began taking prescription painkillers for chronic pain relief, with an astounding 70 percent of these individuals believing that they experience the same or a greater amount of pain than when originally prescribed painkillers.

11 Jun 2010

Takeda receives pricing approval for NESINA in Japan

Furiex Pharmaceuticals, Inc. today confirmed that Takeda Pharmaceutical Company Limited has received pricing approval for NESINA® (alogliptin) in Japan. NESINA, a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, received regulatory approval from the Japanese Ministry of Health, Labour and Welfare on April 16, 2010. Furiex collaborated with Takeda to develop this product.

11 Jun 2010

NeoPharm first-quarter net loss decreases to $1.4 million

NeoPharm, Inc., a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced its first quarter 2010 financial results.

11 Jun 2010

Dabigatran Etexilate anticoagulant as effective as Enoxaparin in preventing venous thromboembolism

Data from the RE-NOVATE® II study presented today at the 15th Annual Congress of the European Hematology Association (EHA) have shown that dabigatran etexilate 220mg once daily is as effective and safe as enoxaparin 40mg in preventing venous thromboembolism (VTE) after total hip replacement surgery.

11 Jun 2010

Eribulin mesylate drug may help extend lives of women with advanced breast cancer

A new drug, based on a natural extract from sea sponge, may help to extend the lives of women with advanced breast cancer, UK scientists have found. A research team at the University of Leeds and St James's Institute of Oncology led an international trial of the new chemotherapy drug, eribulin mesylate.

11 Jun 2010

CinGx safe and effective for treating diabetes, Alzheimer’s and dementia

There is currently no cure for Diabetes, Alzheimer's and Dementia but they can be treated and prevented. Allegiance Equity developed CinGx™ as a safe and effective treatment for these diseases.

11 Jun 2010

Widely used cancer drug bevacizumab can lead to proteinuria, kidney damage: Study

The widely used cancer drug bevacizumab may cause severe loss of protein from the kidney into the urine that can lead to significant kidney damage and can compromise the efficacy of cancer treatment, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The results suggest that physicians should monitor patients' kidney health when prescribing this angiogenesis inhibitor.

11 Jun 2010

Ginkgo extract EGb 761 promotes formation of new nerve cells, cell connections in brain's memory center

US scientists have shown that the Ginkgo extract EGb 761® promotes the formation of new nerve cells and new cell connections in the hippocampus, the brain's memory center. According to Professor Yuan Luo from the University of Maryland, Baltimore, the Ginkgo constituents responsible for these effects are quercetin and bilobalide.

11 Jun 2010

Patheon, Merck expand contract manufacturing agreement

Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry, announced today that it has signed an expanded contract manufacturing agreement with Merck & Co., Inc. (known as MSD outside of the U.S.A. and Canada).

11 Jun 2010

Botox reduces short-term pain in thoracic outlet syndrome patients

Made popular for its ability to smooth wrinkles when injected into the face, Botox - a toxin known to weaken or paralyze certain nerves and muscles - may have another use that goes beyond the cosmetic.

11 Jun 2010

APP Pharmaceuticals to commence marketing of Oxaliplatin Injection in U.S

Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Oxaliplatin Injection (liquid) in the U.S. The U.S. Food and Drug Administration granted approval to market Oxaliplatin Injection in two dosage strengths to Fresenius Kabi Oncology Limited. APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. APP currently markets the lyophilized product, Oxaliplatin for Injection, 50 mg and 100 mg.

11 Jun 2010

Bevacizumab increases risk for proteinuria in cancer patients

Cancer patients treated with the chemotherapy agent bevacizumab (Avastin) may be at an increased risk of severe loss of protein from the kidney into the urine that can lead to significant kidney damage and can compromise the efficacy of cancer treatment. This conclusion stems from a study of more than 12,000 patients by Shenhong Wu, M.D., Ph.D., Principal Investigator, and colleagues at Stony Brook University Medical Center. Their findings are reported in online June 10 in the Journal of the American Society Nephrology (JASN).

11 Jun 2010

NexMed provides update on Vitaros NDS with Health Canada

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today provided an update on the status of its New Drug Submission ("NDS") with Health Canada for Vitaros®, the Company's topical treatment for erectile dysfunction.

11 Jun 2010

Gilead Sciences receives Paragraph IV Certification Notice Letter regarding Lupin's generic Ranexa ANDA

Gilead Sciences, Inc. today announced receipt of a Paragraph IV Certification Notice Letter advising that Lupin Limited submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Ranexa® (ranolazine extended-release tablets).

11 Jun 2010

Pharmaceutical News

Researchers transform yellow fever vaccine to fend off mosquito borne parasites that cause malaria

ACIP's new immunization guidelines for upcoming year

Customs Organization to sign declaration against counterfeit drugs

BIOTECanada congratulates CPHA on 100 years of leadership in public health

FDA grants orphan drug designation for ICT-107

PRA International to host interactive round-table sessions on drug development, lifecycle management

Waismann Method survey: 88% of individuals taken prescription painkillers for chronic pain relief

Takeda receives pricing approval for NESINA in Japan

NeoPharm first-quarter net loss decreases to $1.4 million

Dabigatran Etexilate anticoagulant as effective as Enoxaparin in preventing venous thromboembolism

Eribulin mesylate drug may help extend lives of women with advanced breast cancer

CinGx safe and effective for treating diabetes, Alzheimer’s and dementia

Widely used cancer drug bevacizumab can lead to proteinuria, kidney damage: Study

Ginkgo extract EGb 761 promotes formation of new nerve cells, cell connections in brain's memory center

Patheon, Merck expand contract manufacturing agreement

Botox reduces short-term pain in thoracic outlet syndrome patients

APP Pharmaceuticals to commence marketing of Oxaliplatin Injection in U.S

Bevacizumab increases risk for proteinuria in cancer patients

NexMed provides update on Vitaros NDS with Health Canada

Gilead Sciences receives Paragraph IV Certification Notice Letter regarding Lupin's generic Ranexa ANDA

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News